XNCR

Xencor's stock has experienced volatility and been impacted by several events in the past six months. In Q1 2026, Xencor reported a significantly wider loss, missing analysts' consensus estimates, and the stock slipped in after-hours trading. Analyst sentiment has been mixed, with varied ratings and price targets from different firms. Xencor adopted an Executive Severance Policy with enhanced change-in-control protections for senior executives. Xencor filed for inter partes review of Merus' U.S. Patent Nos. 9,358,286 and 11,926,859. The company has faced challenges, including significant dosing preparation errors in some programs leading to elevated rates of cytokine release syndrome (CRS).